Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00727194 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00727194 is a Phase 2 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT00727194, a Phase 2 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently available.
Interventions
- DRUG Placebo
- DRUG eculizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00727194
The ClinicalTrials.gov registry entry for NCT00727194 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00727194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00727194 about?
NCT00727194 is a clinical study titled "Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis". The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently ava...
What is the current status of trial NCT00727194?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2008-10. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00727194?
The interventions under investigation include: Placebo (DRUG), eculizumab (DRUG).
Who is sponsoring clinical trial NCT00727194?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.